Back to Louisiana

HB1199 • 2026

INSURANCE/HEALTH: Provides relative to health insurance coverage for genetic testing and the treatment of SCN2A-associated medical conditions (EG1 NO IMPACT See Note)

INSURANCE/HEALTH: Provides relative to health insurance coverage for genetic testing and the treatment of SCN2A-associated medical conditions (EG1 NO IMPACT See Note)

Healthcare
Passed Legislature

This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.

Sponsor
Edmond Jordan
Last action
2026-05-29
Official status
Adopted in House concurrence
Effective date
Not listed

Plain English Breakdown

Checked against official source text during the last sync.

Health Insurance Coverage for Genetic Testing and SCN2A-Related Conditions

This bill requires health insurance plans to cover genetic testing for SCN2A-associated medical conditions and the necessary treatments related to these conditions.

What This Bill Does

  • Requires health insurance plans to provide coverage for genetic tests that diagnose SCN2A-related disorders when ordered by a doctor or advanced practice provider.
  • Mandates health insurance plans to pay for medically necessary treatments for SCN2A-associated medical conditions, including medications and therapies.
  • Specifies that the decision on whether treatment is medically necessary must come from the patient's treating physician or an advanced practice provider.
  • Allows health insurance companies to require prior approval before covering certain services but only if this rule applies equally to all other benefits.
  • Ensures that people cannot be denied coverage for genetic testing or treatments based on pre-existing conditions, disability, or developmental status.

Who It Names or Affects

  • People with SCN2A-associated medical conditions and their families
  • Health insurance companies in Louisiana

Terms To Know

Genetic testing
Tests that look for changes in a person's genes to diagnose or predict certain diseases.
Medically necessary treatment
Health services needed to treat, cure, or manage health conditions according to accepted medical standards.

Limits and Unknowns

  • The bill does not apply to limited benefit health insurance policies.
  • It is unclear when the governor will sign this bill into law.

Amendments

These notes stay tied to the official amendment files and metadata from the legislature.

Plain English: The amendment clarifies that family members must be included in the enrollee's health insurance plan to qualify for genetic testing and treatment coverage for SCN2A-associated medical conditions.

  • Clarifies that a family member must be covered under the same health insurance plan as the enrollee to be eligible for genetic testing and treatment coverage.
  • Prohibits denial of coverage based on disability, developmental status, or pre-existing conditions.
  • The amendment text does not provide specific details about how the technical changes mentioned will affect the bill.

Plain English: The amendment adds language requiring that genetic testing and treatment for SCN2A-associated medical conditions be determined to be medically necessary by a health coverage plan.

  • Adds the requirement that genetic testing and treatments covered under health insurance must be deemed medically necessary by the health coverage plan.
  • The amendment text does not provide details on how 'medically necessary' will be defined or what specific SCN2A-associated medical conditions are included.
  • It is unclear if this change affects all types of health insurance plans or only certain ones.

Plain English: The amendment adds language requiring that genetic testing and treatments for SCN2A-associated medical conditions be determined to be medically necessary by a health coverage plan before being covered.

  • Adds the requirement that genetic testing and treatment for SCN2A-associated medical conditions must be deemed medically necessary by a health insurance plan in order to be covered.
  • The amendment text does not provide details on how 'medically necessary' will be defined or determined, which could affect its implementation.

Plain English: The amendment to HB1199 is about agreeing with changes made by the Senate regarding health insurance coverage for genetic testing and treatment of SCN2A-associated medical conditions.

  • Agrees with Senate amendments related to health insurance coverage for genetic testing and treatment of SCN2A-associated medical conditions.
  • The official amendment text does not provide specific details about the changes made by the Senate, only that it is concurring in those amendments.

Plain English: The amendment makes small changes to improve clarity and consistency in the bill text.

  • Changes 'cost sharing' to 'cost-sharing' on page 1, line 6.
  • Adds words after 'member' on page 1, line 18 to specify coverage under the enrollee's policy.
  • Removes a comma after 'include' on page 2, line 15.
  • The amendment does not provide additional details about how these changes will affect the bill's overall impact.

Plain English: The amendment makes small changes to improve clarity and consistency in the bill text.

  • Changes 'cost sharing' to 'cost-sharing' on page 1, line 6.
  • Adds words after 'member' on page 1, line 18 to specify coverage under the enrollee's policy.
  • Removes a comma after 'include' on page 2, line 15.
  • The amendment does not provide additional context about why these changes are necessary or what impact they will have.

Bill History

  1. 2026-05-29 H

    Read by title, roll called, yeas 95, nays 0, Senate amendments concurred in.

  2. 2026-05-29 H

    Scheduled for concurrence on 05/29/2026.

  3. 2026-05-28 H

    Received from the Senate with amendments.

  4. 2026-05-28 S

    The amended bill was read by title, passed by a vote of 32 yeas and 0 nays, and ordered returned to the House. Motion to reconsider tabled.

  5. 2026-05-27 S

    Reported without Legislative Bureau amendments. Read by title and passed to third reading and final passage.

  6. 2026-05-27 S

    Rules suspended. Reported with amendments. Rules suspended. Committee amendments read and adopted. Read by title and referred to the Legislative Bureau.

  7. 2026-05-26 S

    Read by title. Recommitted to the Committee on Insurance.

  8. 2026-05-26 S

    Rules suspended. Recalled from Committee.

  9. 2026-05-21 S

    Read second time by title and referred to the Committee on Judiciary B.

  10. 2026-05-20 S

    Received in the Senate. Read first time by title and placed on the Calendar for a second reading.

  11. 2026-05-20 H

    Read third time by title, roll called on final passage, yeas 94, nays 0. Finally passed, title adopted, ordered to the Senate.

  12. 2026-05-19 H

    Scheduled for floor debate on 05/20/2026.

  13. 2026-05-19 H

    Read by title, passed to 3rd reading.

  14. 2026-05-19 H

    Discharged from the Committee on Appropriations.

  15. 2026-04-27 H

    Read by title, amended, ordered engrossed, recommitted to the Committee on Appropriations.

  16. 2026-04-23 H

    Reported with amendments (10-0).

  17. 2026-04-01 H

    Read by title, under the rules, referred to the Committee on Insurance.

  18. 2026-03-31 H

    Read by title. Lies over under the rules.

Official Summary Text

INSURANCE/HEALTH: Provides relative to health insurance coverage for genetic testing and the treatment of SCN2A-associated medical conditions (EG1 NO IMPACT See Note)

Current Bill Text

Read the full stored bill text
HLS 26RS-2096 ENGROSSED
2026 Regular Session
HOUSE BILL NO. 1199
BY REPRESENTATIVE JORDAN
INSURANCE/HEALTH: Provides relative to health insurance coverage for genetic testing
and the treatment of SCN2A-associated medical conditions
1 AN ACT
2 To enact R.S. 22:1049.1, relative to health insurance; to require coverage for genetic testing
3 for SCN2A associated disorders; to require coverage for medically necessary
4 treatment of SCN2A associated medical conditions; to provide for definitions; to
5 provide for medical necessity determinations; to provide for coverage standards; to
6 provide for prior authorization and cost sharing requirements; to provide for
7 effectiveness; and to provide for related matters.
8 Be it enacted by the Legislature of Louisiana:
9 Section 1. R.S. 22:1049.1 is hereby enacted to read as follows:
10 §1049.1. Requirements for coverage for genetic testing and treatment of
11 SCN2A-associated medical conditions
12 A. For the purpose of this Section, the following terms have the meanings
13 ascribed to them:
14 (1) "Genetic testing" means a laboratory method used to detect changes in
15 genes, gene expression, or chromosomes in a person’s cells or tissues. Genetic
16 testing may be done to look for inherited changes in a person's genes that may be a
17 sign that the person has an increased risk of developing a specific disease or
18 condition or of having a child or other family member with the disease or condition.
19 (2) "Health coverage plan" means any hospital, health, or medical expense
20 insurance policy, hospital or medical service contract, employee welfare benefit plan,
Page 1 of 4
CODING: Words in struck through type are deletions from existing law; words underscored
are additions.
HLS 26RS-2096 ENGROSSED
HB NO. 1199
1 contract or agreement with a health maintenance organization or a preferred provider
2 organization, health and accident insurance policy, or any other insurance contract
3 of this type, including a group insurance plan and the Office of Group Benefits
4 programs.
5 (3) "Medically necessary treatment" means health services necessary for the
6 diagnosis, treatment, cure, or alleviation of health conditions, illnesses, injuries, or
7 diseases. These services must be necessary and appropriate to address the specific
8 health issue or its associated symptoms, and must adhere to the generally accepted
9 standards of medical care within the community.
10 (4) "SCN2A" refers to a gene located on chromosome 2, which provides
11 critical instructions for the synthesis of a sodium channel protein essential for
12 neurotransmission in the brain. The SCN2A gene encodes a voltage-gated sodium
13 channel that plays a pivotal role in the generation of neuronal action potentials.
14 Pathogenic variants of the SCN2A gene are associated with a wide spectrum of
15 neurodevelopmental disorders, which may include, but are not limited to neonatal
16 or infantile onset epilepsy, developmental delay, autism spectrum disorder,
17 intellectual disability, and movement disorders.
18 B. Any health coverage plan delivered, issued for delivery, renewed, or
19 otherwise contracted for in this state on or after January 1, 2027, shall provide
20 coverage for genetic testing to diagnose SCN2A-associated medical conditions when
21 ordered by a treating physician or advanced practice provider and determined to be
22 medically necessary by the health coverage plan.
23 C. A health coverage plan shall provide coverage for medically necessary
24 treatment of SCN2A-associated medical conditions, including but not limited to:
25 (1) Anti-seizure medications and other pharmacologic therapies.
26 (2) Rehabilitative and habilitative services, including physical, occupational,
27 speech, and behavioral therapies.
28 (3) Medically necessary durable medical equipment, assistive technology,
29 and adaptive devices.
Page 2 of 4
CODING: Words in struck through type are deletions from existing law; words underscored
are additions.
HLS 26RS-2096 ENGROSSED
HB NO. 1199
1 (4) Nutritional, feeding, and gastrointestinal management services.
2 (5) Any additional treatment determined to be medically necessary by the
3 treating physician or advanced practice provider.
4 D. Medical necessity shall be determined by the enrollee’s treating physician
5 or advanced practice provider. Any denial of coverage based on medical necessity
6 shall be in writing and shall include the reasons for denial and an explanation of how
7 the request does not meet medical necessity standards. Denials may be appealed
8 pursuant to R.S. 22:1121 et seq.
9 E. A health coverage plan may require prior authorization for services
10 covered under this Section if such procedures are applied in a nondiscriminatory
11 manner and are no more restrictive than those applied to other benefits.
12 F. A health coverage plan may impose copayments, deductibles, or
13 coinsurance amounts on benefits required by this Section. Such cost-sharing shall
14 not be greater than that applied to other medical or surgical benefits under the plan.
15 G. A health coverage plan shall not deny coverage for genetic testing or
16 medically necessary treatment under this Section on the basis of disability,
17 developmental status, or preexisting condition.
18 H. Benefits required by this Section shall be considered rehabilitative or
19 habilitative services and devices for purposes of any state or federal requirement for
20 coverage of essential health benefits.
21 I. The provisions of this Section do not apply to limited benefit health
22 insurance policies or contracts.
23 Section 2. This Act shall become effective upon signature by the governor or, if not
24 signed by the governor, upon expiration of the time for bills to become law without signature
25 by the governor, as provided by Article III, Section 18 of the Constitution of Louisiana. If
26 vetoed by the governor and subsequently approved by the legislature, this Act shall become
27 effective on the day following such approval.
Page 3 of 4
CODING: Words in struck through type are deletions from existing law; words underscored
are additions.
HLS 26RS-2096 ENGROSSED
HB NO. 1199
DIGEST
The digest printed below was prepared by House Legislative Services. It constitutes no part
of the legislative instrument. The keyword, one-liner, abstract, and digest do not constitute
part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]
HB 1199 Engrossed 2026 Regular Session Jordan
Abstract: Requires health coverage plans to provide insurance coverage for genetic testing
to diagnose SCN2A-associated medical conditions and medically necessary
treatments related to such conditions.
Proposed law defines certain terms. Proposed law mandates that any health coverage plan
delivered, issued for delivery, renewed, or otherwise contracted in this state on or after Jan.
1, 2027, shall provide insurance coverage for genetic testing specifically for the diagnosis
of SCN2A-associated medical conditions when such testing is ordered by a treating
physician or an advanced practice provider and determined to be medically necessary by the
health coverage plan.
Proposed law mandates coverage for medically necessary treatment of SCN2A-associated
medical conditions. This includes but is not limited to: anti-seizure medications and other
pharmacologic therapies; rehabilitative and habilitative services; medically necessary
durable medical equipment, assistive technology, and adaptive devices; nutritional, feeding,
and gastrointestinal management services; as well as any additional treatments deemed
medically necessary by the treating physician, advanced practice provider and the health
coverage plan.
Proposed law stipulates that the determination of medical necessity be made by the enrollee's
treating physician or advanced practice provider. In the event of a denial of coverage,
written notification must be provided, along with clear and detailed reasoning for the denial.
Additionally, such denials may be appealed in accordance with existing laws.
Proposed law permits the implementation of prior authorization procedures, provided these
are applied in a non-discriminatory manner and no more restrictively than those applied to
other medical benefits. Cost-sharing requirements may be imposed, but they can not exceed
those applicable to other medical or surgical benefits under the same plan.
Proposed law prohibits any denial of coverage based on disability, developmental status, or
pre-existing conditions. Proposed law clarifies that the mandated benefits will encompass
rehabilitative and habilitative services and devices as part of the essential health benefits.
Proposed law does not extend to limited benefit health insurance policies or contracts.
Effective upon signature of governor or lapse of time for gubernatorial action.
(Adds R.S. 22:1049.1)
Summary of Amendments Adopted by House
The Committee Amendments Proposed by House Committee on Insurance to the
original bill:
1. Clarify the coverage requirement by mandating that services must be ordered by
a provider and also deemed medically necessary by the health coverage plan to
qualify for coverage.
2. Make technical changes.
Page 4 of 4
CODING: Words in struck through type are deletions from existing law; words underscored
are additions.